TRIM21 Expression as a Prognostic Biomarker for Progression-Free Survival in HNSCC.
IHC
TRIM21
head and neck squamous cell carcinoma (HNSCC)
immune cell infiltration
prognostic biomarker
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
07 Mar 2023
07 Mar 2023
Historique:
received:
09
02
2023
revised:
02
03
2023
accepted:
05
03
2023
medline:
30
3
2023
entrez:
29
3
2023
pubmed:
30
3
2023
Statut:
epublish
Résumé
Patients with head and neck squamous cell carcinoma (HNSCC) continue to have a rather poor prognosis. Treatment-related comorbidities have negative impacts on their quality of life. TRIM21 is a cytosolic E3 ubiquitin ligase that was initially described as an autoantigen in autoimmune diseases and later associated with the intracellular antiviral response. Here, we investigated the role of TRIM21 as a biomarker candidate for HNSCC in predicting tumor progression and patient survival. We analyzed TRIM21 expression and its association with clinical-pathological parameters in our HNSCC cohort using immunohistochemistry. Our HNSCC cohort included samples from 419 patients consisting of primary tumors (
Identifiants
pubmed: 36982215
pii: ijms24065140
doi: 10.3390/ijms24065140
pmc: PMC10048917
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
SS-A antigen
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : University of Luebeck, postdoctoral qualification grant
ID : H01-2022
Références
Front Med (Lausanne). 2021 Jan 27;8:622330
pubmed: 33585526
Pharmacol Res. 2021 Nov;173:105866
pubmed: 34474103
Cancers (Basel). 2022 Dec 10;14(24):
pubmed: 36551565
Lancet Oncol. 2010 Aug;11(8):781-9
pubmed: 20451455
Front Pharmacol. 2022 Mar 24;13:821344
pubmed: 35401182
Clin Cancer Res. 2021 Jan 15;27(2):632-644
pubmed: 33109740
Int J Mol Sci. 2022 May 03;23(9):
pubmed: 35563463
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
Oral Oncol. 2017 Feb;65:8-15
pubmed: 28109473
Nat Immunol. 2013 Apr;14(4):327-36
pubmed: 23455675
Oncology. 2015;89(3):125-36
pubmed: 25967534
Exp Ther Med. 2022 Nov 09;24(6):761
pubmed: 36561971
Eur Arch Otorhinolaryngol. 2022 Jul;279(7):3657-3664
pubmed: 34905065
Lancet. 2019 Jul 6;394(10192):64-80
pubmed: 31178151
Int J Mol Sci. 2020 Jul 31;21(15):
pubmed: 32752128
Int J Mol Sci. 2020 Dec 29;22(1):
pubmed: 33383632
Arch Pathol Lab Med. 2018 May;142(5):559-597
pubmed: 29251996
J Pers Med. 2022 Jun 17;12(6):
pubmed: 35743773
Ann Oncol. 2019 Jan 1;30(1):68-75
pubmed: 30407504
Front Pharmacol. 2022 Jan 20;12:753387
pubmed: 35126105
J Immunol. 2013 Oct 1;191(7):3753-63
pubmed: 23975864
J Biomed Sci. 2020 Jan 31;27(1):30
pubmed: 32005234
Mod Pathol. 2010 Aug;23(8):1061-7
pubmed: 20473283
J Clin Oncol. 2015 Oct 10;33(29):3235-42
pubmed: 26351338
J Exp Med. 1988 May 1;167(5):1560-71
pubmed: 3367095
Cancer Lett. 2021 Jun 28;508:115-126
pubmed: 33794309
Int J Med Sci. 2021 Jun 11;18(13):2997-3003
pubmed: 34220328
Bioengineered. 2022 Mar;13(3):6024-6035
pubmed: 35226825
Sci Rep. 2017 Dec 4;7(1):16878
pubmed: 29203879
J Immunol. 2016 Apr 15;196(8):3452-3459
pubmed: 26962230
Front Immunol. 2021 Sep 06;12:738473
pubmed: 34552597
Int J Mol Sci. 2020 Jan 28;21(3):
pubmed: 32013033
J Intern Med. 2015 Sep;278(3):323-32
pubmed: 25880119
Int J Mol Sci. 2020 Aug 01;21(15):
pubmed: 32752295
Am J Cancer Res. 2020 Jan 01;10(1):114-130
pubmed: 32064156
Cancer Manag Res. 2018 Sep 20;10:3687-3696
pubmed: 30288100
Prostate Cancer Prostatic Dis. 2012 Jun;15(2):165-9
pubmed: 22231490
Tumour Biol. 2015 Nov;36(11):8761-72
pubmed: 26055142
Oral Oncol. 2015 Oct;51(10):888-900
pubmed: 26209066
Cancers (Basel). 2022 May 20;14(10):
pubmed: 35626129
Cell Mol Gastroenterol Hepatol. 2021;11(5):1369-1385
pubmed: 33482392
J Clin Oncol. 2015 Oct 10;33(29):3305-13
pubmed: 26351341